HOME >> BIOLOGY >> NEWS
An insecure role for Securin in chromosome segregation

A critical aspect of cell division, or mitosis, is that the progeny cells must receive the full complement of chromosomes. Failure of this mechanism, which sometimes happens in cancer cells, leads to rampant chromosome loss and mutations that encourage proliferation and increase instability. Understanding how normal cells unerringly transmit a full chromosome set to their daughters has long been an important part of the fight against cancer.

In a new study published online in the open-access journal PLoS Biology, Katrin Pfleghaar, Michael Speicher, and colleagues reinvestigate the cell's ability to undergo mitosis when missing a key protein, securin. Securin is a chaperone protein that regulates an enzyme that initiates the segregation of the sister chromatids during mitosis. They found that, contrary to previous reports, human cells devoid of the securin protein, which initially suffer widespread chromosome losses, can actually recover after a certain time has passed. In fact, cells with abnormal mitoses and chromosome counts became rarer until, after a few weeks, the cells appeared indistinguishable from their relatives with an intact securin gene. Pfleghaar and her colleagues speculate that securin normally plays an important role in mitoses, but that in its absence, cells tap into compensatory mechanisms to restore proper chromosome segregation.

The implications for cancer treatment are potentially great, as mathematical models of cancer growth do not usually include the possibility that cell populations might recover from chromosomal instability. In addition, such recovery from securin loss, like that seen here, might interfere with therapies that aim to kill cancer cells by exacerbating their chromosome losses.


'"/>

Contact: Paul Ocampo
press@plos.org
415-624-1224
Public Library of Science
28-Nov-2005


Page: 1

Related biology news :

1. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer
2. Double identities lie behind chromosome disorders
3. St. Jude study yields secrets of chromosome movement
4. Physicist cracks womens random but always lucky choice of X chromosome
5. Researchers shed light on shrinking of chromosomes
6. Researchers attach genes to minichromosomes in maize
7. Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks
8. New technique will produce a better chromosome map
9. Short chromosomes put cancer cells in forced rest
10. Shortening chromosomes cause for earlier cancer onset in families with rare syndrome
11. The pull of bacterial chromosome segregation

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: insecure role for Securin chromosome segregation

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: